Von Hippel

Merck’s Novel HIF-2α Inhibitor Showed an Objective Response Rate of Nearly 30% in Patients with von Hippel-Lindau (VHL) Disease-Associated Clear Cell Renal Cell Carcinoma

Retrieved on: 
Wednesday, May 13, 2020
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Health, Clinical medicine, Medicine, Rare diseases, Autosomal dominant disorders, Genodermatoses, Syndromes, Von Hippel–Lindau disease, Von Hippel–Lindau tumor suppressor, Renal cell carcinoma, Merck & Co., Von Hippel, MK-6482, Merck

Von Hippel-Lindau disease is a rare hereditary condition affecting multiple organs, which puts patients at risk for several cancers, including renal cell carcinoma.

Key Points: 
  • Von Hippel-Lindau disease is a rare hereditary condition affecting multiple organs, which puts patients at risk for several cancers, including renal cell carcinoma.
  • Follow Merck on Twitter via @Merck and keep up to date with ASCO news and updates by using the hashtag #ASCO20.
  • This study is a Phase 2, open-label, single-arm trial evaluating MK-6482 for the treatment of VHL-associated ccRCC (ClinicalTrials.gov, NCT03401788 ).
  • Patients received MK-6482 120 mg orally once daily until disease progression, unacceptable toxicity, or investigators or patients decision to withdraw.

Genetic Cancer Patients Report COVID-19 Crisis Impacts Medical Care

Retrieved on: 
Wednesday, April 22, 2020
Medicine, Cancer, Health, Autosomal dominant disorders, Rare diseases, Genodermatoses, Syndromes, Von Hippel–Lindau disease, Von Hippel–Lindau tumor suppressor, Neuroendocrine tumor, Von Hippel, Endolymphatic sac tumor

VHL, or von Hippel-Lindau disease, is a genetic disorder characterized by tumors in up to ten areas of the body.

Key Points: 
  • VHL, or von Hippel-Lindau disease, is a genetic disorder characterized by tumors in up to ten areas of the body.
  • The tumors can be benign or cancerous, and appear and grow unpredictably throughout a patient's life.
  • Renal and pancreatic neuroendocrine cancers, paralysis, loss of vision and hearing, are among the dangers faced by VHL patients.
  • The VHL Alliance (VHLA) is the preeminent resource and clearinghouse for those affected by von Hippel-Lindau disease, including patients, caregivers, researchers, and the medical community.